BMY-28100 IN THE FIELD OF SURGERY

We investigated BMY-28100, a newly synthesized cephalosporin compound, for its clinical efficacy and side effects. BMY-28100 500-2000mg/d was administered to 47 patients with skin and soft tissue infections. Its clinical efficacy was: excellent 25, good 14, fair 6 and poor 2, with an efficacy rate o...

Full description

Saved in:

Bibliographic Details
Published in:	CHEMOTHERAPY Vol. 37; no. Supplement3; pp. 731 - 738
Main Authors:	SAKAI, KATSUJI, MORIMOTO, KEN, NAKATANI, SHUICHI, KINOSHITA, HIROAKI, UEDA, TAKAMI, HIRATA, SANAE, MORIMOTO, YUZURU, FUJIMOTO, MIKIO, OHNO, KOHICHI
Format:	Journal Article
Language:	English Japanese
Published:	Japanese Society of Chemotherapy 1989
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We investigated BMY-28100, a newly synthesized cephalosporin compound, for its clinical efficacy and side effects. BMY-28100 500-2000mg/d was administered to 47 patients with skin and soft tissue infections. Its clinical efficacy was: excellent 25, good 14, fair 6 and poor 2, with an efficacy rate of 83.0%. In 43 cases, 55 bacterial strains were identified and almost all of them, except 2 strains of Staphylococcus aureus, were eliminated (96.4%). No apparent side effects were observed. Although elevation of the thrombocyte-count and GOT level in peripheral blood was observed, no data were obtained.
ISSN:	0009-3165 1884-5894
DOI:	10.11250/chemotherapy1953.37.Supplement3_731